Search results

Selected filters:

Analysis
Life Sciences

Article type

Topic

Sector

Regions

Year

325 results found for your search

Sort options
16 July 2019

Gilead’s unique $5.1 billion licensing deal shows the range of IP monetisation options open to biotech sector

New boss explains that the Big Pharma company will seek out “diverse and creative” asset partnerships – rather than large acquisitions – to boost its pipeline

12 July 2019

Delhi judge orders IP appeal board to start hearing cases again

The body has been paralysed by vacancies for years and more than 600 appeals of patent office decisions are in limbo

11 July 2019

New analysis shows impact that “blockbuster” decisions are having on patent litigation

RPX data highlights big drop in success of early 101 challenges in district court cases; if trend continues would point to shift in balance of power back to IP owners

11 July 2019

CAFC says Congress or SCOTUS must address diagnostics patentability controversy

Decision denying en banc rehearing of much-watched Athena case means that hopes for 101 reform now hinge on legislators and the Supreme Court

08 July 2019

Intel, Alphabet and Qualcomm among big fallers as largest US IP owners cut back on patenting

Latest ranking from IPO of top 300 companies shows an overall decline in the market as the mantra of quality over quantity continues to take effect

05 July 2019

Get ready for the first CRISPR patent pool

In an exclusive interview, MPEG LA’s Kristin Neuman says that a pool is on its way despite the UCal v Broad stand-off and talks about the future of licensing in biotech’s ‘golden age’

03 July 2019

Law firm’s patent attorney deal shows changing face of IP practice in the UK

Lewis Silkin’s acquisition of Ablett & Stebbing is a first and demonstrates just how far things have moved in a once conservative market

02 July 2019

AbbVie’s Allergan play designed to mitigate Humira patent cliff

The $63 billion purchase is designed to mitigate the effects of losing the exclusive rights to the world’s best selling drug

01 July 2019

Slump at the PTAB continues with first half numbers showing big drop in new reviews

Data suggests PTO director Iancu’s IPR reforms are continuing to bite; while despite jump in Q2, district court litigation remains broadly flat for first six months of 2019

28 June 2019

New battle in CRISPR patent war adds to the uncertainty surrounding the technology

New interference proceeding gives the University of California another shot at claiming exclusive rights to CRISPR-Cas9 gene-editing in human, animal and plant cells

26 June 2019

Despite UK High Court setback for Pfizer, Arrow declarations remain a valuable litigation tool

The latest judgment is one of only a few to provide an indication of when the courts will grant the pre-emptive litigation defence remedy, which was issued for the first time in 2017

24 June 2019

New research highlights importance of US government on patented technologies

Federal support particularly crucial for start-ups with Department of Defense leading the way among state agencies

21 June 2019

US strategy for state-owned patents under increasing scrutiny amidst drug price controversies

The government is facing calls to better leverage its own IP in the public interest following revelations about PrEP rights

20 June 2019

Another year, another benchmarking survey and the EPO is top once more

Boost for António Campinos as he ends the first year of his presidency; and good news, too, for USPTO head Andrei Iancu

18 June 2019

Pfizer’s $11 billion Array purchase shows oncology assets continue to drive pharma transactions

The world’s largest life sciences company demonstrates that it is still a major presence in the M&A landscape, despite its stated focus on organic growth.